Top Medical News Today
Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.
Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended.
While mouse models have historically been helpful in the research of immunotherapies, genetic testing and clinical models may play a role in the near future. These pre-clinical models have been criticized for some of their limitations, but Marcus Bosenberg, MD, PhD, confirms their current relevance and clinical applicability.
Michael Morse, MD, discusses treatment considerations and options for 2 cases of patients with colorectal cancer
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) for use as a treatment for patients with refractory classical Hodgkin lymphoma.
View More >
Jeffery S. Weber, MD, PhD, discusses treatment considerations and options for 3 cases of patients with metastatic melanoma.
Nivolumab Approved for Head and Neck Cancer
The FDA has approved the PD-1 inhibitor nivolumab as a treatment for patients with metastatic or recurrent squamous cell carcinoma of the head and neck following progression on platinum-based therapy.
Wierda Discusses Current Questions in Frontline CLL Treatment
William G. Wierda, MD, PhD, discusses which groups of CLL patients may benefit from ibrutinib versus chemoimmunotherapy and clinical trials that may provide further clarification.
Blinatumomab Receives FDA Approval for Acute Lymphoblastic Leukemia
Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
NDA for Neratinib in HER2-Positive Breast Cancer Accepted by FDA
A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer